2 recruiting, 1 not yet recruiting. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Fei Gao: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension Transjugular intrahepatic portosystemic shunt (TIPS), Donafenib - Hepatocellular Carcinoma with PVTT | Phase 2 | Recruiting | Fei Gao | 40 | 2024-10-08 | 2024-10-17 |
| Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP), Panretinal photocoagulation(PRP) - Non Proliferative Diabetic Retinopathy(NPDR) | Not applicable | Not yet recruiting | Fei Gao | 249 | 2024-05-05 | 2024-03-15 |
| TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS) - Hepatocellular Carcinoma | Phase 2 | Recruiting | Fei Gao | 30 | 2022-12-01 | 2024-10-16 |
Portasystemic Shunt, Transjugular Intrahepatic (2) · donafenib (1)
China (3)